CompletedNCT00796081

A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

Medication studyAges 10–17

The study in practice

Understand this study

Listed age limits: 10 years to 17 years.

Study clarity

Study start dateJanuary 2006

Recruitment status: Completed
Enrollment listed in the registry: 25
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: Not clearly listed
Age range: From 10 Years to 17 Years
Official registry ID: NCT00796081
Official title: Show the full official title
Open-label Study to Evaluate the Safety and Pharmacokinetics of Single- and Multiple-dose Extended-release OROS Paliperidone in Pediatric Subjects (=10 to =17 Years of Age) With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

Completed

Locations not listed

FAQ

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including ER OROS paliperidone, paliperidone ER.

Who was this study for?

Listed age limits: 10 years to 17 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.